The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
May 17th 2024
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
AAM White Paper Offers Causes and Solutions to the US Generic Drug Shortage
July 30th 2023A white paper crafted by the Association for Accessible Medicines (AAM) outlined that main causes of generic drug shortages and recommended several actions for stakeholders to remedy current shortages and prevent future ones.
Read More
Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price
July 21st 2023Even at a steep discount, the list prices of new adalimumab biosimilars are significantly higher than the original price of the originator product (Humira), highlighting how dramatically its list price has risen over the years.
Read More
Patient Education Can Prevent Nocebo Effect With Adalimumab Biosimilars, Explains Laura Wingate
July 15th 2023As Humira biosimilars enter the market, patient education about biosimilars is crucial to prevent the nocebo effect when patients switch from the reference product, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Watch
Oncology Practices Made Shifts Toward Biosimilar Use, but Payer Challenges Remain
July 5th 2023Two abstracts presented at the 2023 American Society of Clinical Oncology annual meeting evaluated biosimilar adoption across oncology practices and highlighted the role payers play in preventing or promoting adoption.
Read More
Dr Scott Soefje Says New Biosimilar Workflow "Completely Simplified the System"
June 28th 2023Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic, explains how education can help with biosimilar adoption and how an updated biosimilar workflow has simplified the prior authorization process.
Watch
SmithRx to Offer Adalimumab Biosimilar Yusimry at 90% Discount to Humira
June 14th 2023The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost of the reference product, Humira.
Read More
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 8th 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
Read More
Mandatory Switch Policies Drive Biosimilar Uptake, Reduce Costs
June 2nd 2023Abstracts presented at EULAR 2023 highlighted the impact that a mandatory switching policy had on biosimilar uptake in British Columbia, Canada, and the lack of uptake when no such policy was in place in the United States.
Read More
Provider Barriers in Uptake of Biosimilars: Case Study on Filgrastim
Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.
Read More
Pegfilgrastim Biosimilar Fylnetra Launches in the United States
May 19th 2023Amneal Pharmaceuticals this week launched its pegfilgrastim biosimilar, Fylnetra (pegfilgrastim-pbbk), for the treatment and prevention of febrile neutropenia, making it the sixth biosimilar referencing Neulasta to enter the US market.
Read More
Patient Joins PQA23 Panel on IRA’s Potential Impact on Medication Access, Affordability
May 13th 2023At the Pharmacy Quality Alliance (PQA) 2023 Annual Meeting, a patient joined a panel to give insight into the challenges of living with a chronic illness and what he sees as the pros and cons of the Inflation Reduction Act (IRA).
Read More
Dr Fran Gregory Discusses the Impact of the New Wave of Biosimilars on Rebate Practices
May 8th 2023Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the role the new wave of biosimilars will have on rebate practices for both pharmacy benefit managers (PBMs) and payers.
Watch
Despite Concerns Over Extrapolation, Bevacizumab Biosimilars Are Widely Used in mCRC
May 5th 2023A review article investigating the use of bevacizumab biosimilars found that despite lingering concerns about their usage for extrapolated indications, bevacizumab biosimilars are regularly used in metastatic colorectal cancer (mCRC) even though clinical tests only evaluate them in patients with lung cancer.
Read More
Margaret Rehayem Discusses How Employers Should Look at Their Humira Biosimilar Strategy
May 3rd 2023Oncology has been an easy area for employers to adopt biosimilars because of the rising costs in the space, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions. Now that multiple adalimumab (Humira) biosimilars are hitting the US market, employers should take a step back to review their current strategy around the drug.
Watch
Margaret Rehayem: Rebates Remain Influential and a Barrier to Biosimilar Adoption for Employers
April 28th 2023Rebates remain very attractive for many employers, but they should push back on the reliance on rebates that may be preventing biosimilars from being added to formularies, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
Watch
Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars
April 22nd 2023A study assessing factors that may determine a commercial health plan’s likelihood of covering a biosimilar found that biosimilars that are cancer therapies, used to treat children, indicated for highly prevalent conditions, or only competing against the originator were more likely to have coverage restrictions.
Read More
There Remains a Need to Educate Employers, Employees on Biosimilars: Margaret Rehayem
April 20th 2023While employers fall on a spectrum when it comes to knowledge and understanding of biosimilars, there does remain a need to educate them, as well as for them to educate their employees, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
Watch